BridgeBio Pharma Inc. reported its financial results for the second quarter ending June 30, 2025. The company recorded a total revenue of $110.6 million, which includes $71.5 million from U.S. Attruby net product revenue, $1.6 million from royalty revenue, and $37.5 million in license and services revenue. The company experienced a net loss attributable to common stockholders of $181.9 million for the three months ended June 30, 2025, compared to $73.5 million in the same period of the previous year. For the six months ended June 30, 2025, the net loss was $349.3 million, significantly higher than the $108.7 million recorded in the same period in 2024. The increase in net loss was influenced by factors including a decrease in gain on deconsolidation of a subsidiary by $126.3 million, an increase in interest expense by $33.4 million, and an increase in net loss from equity method investments by $27.8 million, partially offset by a decrease in losses on extinguishments of debt by $5.4 million. Since the FDA approval of Attruby in November 2024, a total of 3,751 unique patient prescriptions have been written by 1,074 unique healthcare providers as of August 1, 2025.